News Releases
This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
10 24 2023 Third quarter revenues of $2.30 billion, down 7.7% from 2022 Third quarter reported diluted earnings per share ("EPS") of $1.96, down 9.7% from 2022; and adjusted diluted EPS of $2.22, down 5.9%...
-
07 26 2023 Quest Diagnostics Reports Second Quarter 2023 Financial Results; Updates Guidance for Full Year 2023Second quarter revenues of $2.34 billion, down 4.7% from 2022 Second quarter reported diluted earnings per share ("EPS") of $2.05, up 4.6% from 2022; and adjusted diluted EPS of $2.30, down 2.5%...
-
07 13 2023 Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer SECAUCUS, N.J. and MELBOURNE, Australia, July 13, 2023 /
-
06 29 2023 June 2023 For more information or to schedule an interview with one of our medical experts, please email mediacontact@questdiagnostics.com. Breaking Science News: Only one in three adults (34%)...
05 08 2023 Please check back to this page periodically for the latest information. To receive these media updates, please email mediacontact@questdiagnostics.com.Beginning February 2023, Quest Diagnostics plans to discontinue providing a monthly COVID-19 media statement, including monthly COVID-19 volume and turnaround time figures. Instead, this media...
-
03 21 2023 New Panels Aimed at the Millions of Americans Still Suffering From COVID-19 Side Effects SECAUCUS, N.J., March 21, 2023 /PRNewswire/ -- The consumer-initiated testing business from the leader in...
-
03 16 2023 Updates 2023-26 compound annual growth rate (CAGR): Revenues expected to grow at mid single-digit rate; adjusted diluted earnings per share (EPS)* expected to grow at high single-digit rate...
-
03 03 2023 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors elected James E. Davis, the company's Chief Executive...
02 16 2023 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Tower Health, a regional integrated healthcare system in Pennsylvania, are teaming up to enhance...
-
02 02 2023 Fourth quarter revenues of $2.33 billion, down 15.0% from 2021 Fourth quarter reported diluted earnings per share ("EPS") of $0.87, down 72.1% from 2021; and adjusted diluted EPS of $1.98, down...